Allogeneic Stem Cell Transplantationin Relapsed Hematological Malignancy: Early GVHD Prophylaxis
Status:
Active, not recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
Determine the relapse-free, donor lymphocyte infusion (DLI)-free survival in patients
receiving the investigational regimen.This is a randomized phase II clinical trial, comparing
two different dosing schedules of mycophyenolate mofetil for graft versus host disease (GVHD)
prevention following allogeneic stem cell transplantation. Risk for relapse, GVHD and
non-relapse mortality will be assessed. Adaptive randomization between two study arms will be
performed based on T cell counts at day 60.